Despite promising effects of H3R antagonists to correct cognitive deficits in preclinical models, which included executive function paradigms, these compounds have borne mixed results in treating CIAS in clinical trials (Egan et al., 2013; Haig et al., 2014; Jarskog et al., 2015; Vohora and Bhowmik, 2012). The gene discussed is HRH3; the disease is Cognitive impairment.